FATE FY 2025 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-51.2% YoY

Gross Profit

-$6M-94.1% margin

Operating Income

-$148M-2222.4% margin

Net Income

-$136M-2051.1% margin

EPS (Diluted)

$-1.15

Cash Flow

Operating Cash Flow

-$106M

Free Cash Flow

-$112M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$319M

Total Liabilities

$112M

Stockholders' Equity

$207M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$14M	-51.2%
Gross Profit	-$6M	$14M	-145.9%
Operating Income	-$148M	-$210M	+29.8%
Net Income	-$136M	-$186M	+26.8%